An update from Mesoblast Limited ( (AU:MSB)) is now available. Mesoblast has received a U.S. FDA Biologics License Application filing number and requested modular review for rexlemestrocel‑L, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results